Myriad Genetics Shares Fall Amid Dour Outlook – Wall Street Journal


Post Registrar
Myriad Genetics Shares Fall Amid Dour Outlook
Wall Street Journal
For the current quarter, Myriad expects revenue between $168 million and $170 million with adjusted earnings in the range of 25 cents to 27 cents a share, well under analysts’ forecasts of $192 million and 42 cents a share. For the 2017 fiscal year
Myriad Genetics shares drop more than 20% on outlook, earningsMarketWatch

all 18 news articles >>

Source: shares – Google News

Sharing information is key – Share Dealing Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd